We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A planned settlement between Aegerion Pharmaceuticals and federal officials will require the company to shell out $40 million and plead guilty to two misdemeanor violations of the FD&C Act, the company disclosed Friday. Read More
The UK’s National Institute for Health and Care Excellence says it will not recommend Bristol-Myers Squibb’s Opdivo, casting doubt on the drug’s cost-effectiveness for people with locally advanced or metastatic non-squamous, non-small-cell lung cancer after chemotherapy. Read More
Clovis Oncology is stopping development of its lung cancer candidate rociletinib after the FDA warned the company of a potential complete response letter. Read More
To bridge the gulf between the promise of biosimilars on drug pricing and the reality, payors should incentivize biosimilar utilization, a new report states. Read More
UK regulators have fined Pfizer $14,000 for failing to explain a questionable claim meant to justify price increases on the generic seizure medication Epanutin. Read More
Members of the Senate Special Committee on Aging took Valeant Pharmaceuticals’ International officials to task over what they called the company’s practice of buying drugs with no generic competition and “jacking up” the prices. Read More
Amgen and Sanofi are the latest companies to climb on the pay-for-performance bandwagon after reaching agreements with insurer Cigna for their respective cholesterol drugs, Repatha and Praluent. Read More